… Mice treated with 2B04/47D11 or LY-CoV555 also showed greater virus breakthrough than
… than the other mAb cocktails, and LY-CoV555 mAb treatment conferred virtually no protection …

… ongoing, with the medication company "Lilly" using LY-CoV555 neutralizing MAbs against
the spike protein. The neutralizing antibody LY-CoV555, at a dosage of 2800 mg, appeared to …

… odds ratio of a better outcome with LY-CoV555 than with placebo using proportional-odds …
the primary safety analysis, which compared LY-CoV555 with placebo with respect to the …

… ); LY-CoV555/LY-CoV016 (synthesized based on bamlanivimab and etesevimab sequences
from Eli Lilly); CT-P59 (synthesized based on regdanvimab sequences from Celltrion); and …

… antibody that can neutralize the wide-type SARS-CoV-2 but failed to target the B.… LY-CoV555
that is a monoclonal antibody isolated from a convalescent COVID-19 patient. LY-CoV555 …

… initiated a Phase 1 study on LY-CoV555 and had completed enrolling patients and … LY-COV555
group was 1.6% compared with 6.3% in the placebo group, suggesting that LY-COV555 …

… binding domain of the SARS-CoV-2 spike protein (S-RBD CoV‑2 ) in evading the
immune surveillance effects elicited by the two Eli Lilly LY-CoV555/bamlanivimab and LY-CoV016/…

… We found that AUC 0-192 hr of all drugs was higher, of which 14F4HL was twice as high
as positive control LY-CoV555, indicating that the total amount of 14F4HL and the elimination …

… of the REGN SARS-CoV-2 cocktail neutralized D614G and Delta but not BA.1 or BA.2.
Similarly, LY-CoV555 and LY-CoV016 neutralized D614G and Delta (although LY-CoV555 had …

… For the human monoclonal antibody, we selected LY-CoV555 to be tested along with the
serum samples in the microneutralisation test (MNT) and used it as our positive control for the …